Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

Published:2017-06 Issue:6 Volume:4 Page:e272-e282
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Davies Andrew,Merli Francesco,Mihaljević Biljana,Mercadal Santiago,Siritanaratkul Noppadol,Solal-Céligny Philippe,Boehnke Axel,Berge Claude,Genevray Magali,Zharkov Artem,Dixon Mark,Brewster Michael,Barrett Martin,MacDonald David

Publisher

Elsevier BV

Subject

Hematology

Reference27 articles.

1. Advances in the management of follicular lymphoma;Seiler;Curr Opin Oncol,2012

2. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration;Frost;Expert Opin Drug Deliv,2007

3. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase;Shpilberg;Br J Cancer,2013

4. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries;De Cock;PLoS One,2016

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology;Advanced Materials;2024-08-20

2. The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations;Trends in Cancer;2024-07

3. Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins;Clinical Pharmacology & Therapeutics;2024-01-18

4. Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development;Clinical Pharmacology & Therapeutics;2024-01-10

5. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01